Nutrition

Vitamins and Supplements to Take on GLP-1 Medications

GLP-1 Companion · 9 min read

GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are remarkably effective at reducing appetite and promoting weight loss. But that same appetite suppression that drives results also dramatically lowers total food intake — and with it, the intake of essential vitamins and minerals. The consequences can be subtle at first and serious over time.

Why GLP-1 Medications Create Nutritional Risk

The mechanisms behind nutritional depletion on GLP-1 therapy are straightforward. When appetite is suppressed by 30–50%, total caloric intake falls substantially. People eat smaller portions, skip meals more often, and frequently reduce or eliminate nutrient-dense but calorically dense foods like red meat, dairy, and fortified grains. The result is a narrower dietary base with less margin for micronutrient needs.

Additionally, GLP-1 medications slow gastric emptying and reduce gastric acid secretion. This directly impairs the absorption of certain nutrients — particularly vitamin B12 and iron — that rely on stomach acid to be released from food proteins. Rapid weight loss also alters the distribution of fat-soluble vitamins like vitamin D, since these are stored in adipose tissue.

The nutritional risks of GLP-1 therapy are real and underrecognized. Proactive monitoring and targeted supplementation are not optional extras — they are part of responsible long-term management.

The 7 Key Nutrients at Risk

1. Vitamin B12

B12 is arguably the highest-priority nutrient to monitor on GLP-1 therapy. Gastric acid is required to cleave B12 from food proteins so it can bind to intrinsic factor for absorption. When gastric acid secretion is reduced, dietary B12 absorption is impaired — even when intake appears adequate. B12 is stored in the liver with a 3–5 year reserve, so deficiency develops slowly and lab values may remain normal for two or more years before dropping. However, subtle neurological symptoms — tingling, memory lapses, fatigue — can appear before any blood test turns abnormal.

• Recommended supplement: 1,000 mcg methylcobalamin daily (active form, does not require conversion)
• Sublingual B12 dissolves under the tongue and bypasses gastric absorption entirely — ideal for GLP-1 users
• Check serum B12 every 6–12 months; also consider methylmalonic acid (MMA) for more sensitive assessment
• Risk is higher with longer duration of therapy, metformin co-use, older age, and reduced meat intake

2. Vitamin D

Vitamin D deficiency is extremely common in the general population, and GLP-1 therapy adds additional complexity. As a fat-soluble vitamin, vitamin D is stored in adipose tissue. During rapid weight loss, fat cells release vitamin D, which can transiently raise serum levels — potentially masking an underlying deficit. Long-term, reduced dietary intake of dairy and fortified foods further compounds the risk.

• Supplement dose: 2,000–5,000 IU vitamin D3 daily is reasonable for most adults on GLP-1 therapy
• Check 25-OH vitamin D levels at baseline and every 6–12 months
• Target serum level: 40–60 ng/mL (100–150 nmol/L) for optimal bone and immune health
• Take with a meal containing fat for best absorption

3. Iron

Iron deficiency is especially prevalent among premenopausal women on GLP-1 medications. As appetite suppression tends to reduce intake of red meat and other high-iron foods, total dietary iron declines. Reduced gastric acid further impairs non-heme iron absorption. Symptoms — fatigue, cold intolerance, difficulty concentrating, and hair loss — overlap significantly with other effects of GLP-1 therapy and can be dismissed or missed.

• Ferritin is the most sensitive and specific marker of iron stores; check at baseline and every 6–12 months
• Supplement if ferritin falls below 30 ng/mL; treatment ferritin target is typically 50–100 ng/mL
• Take iron supplements away from calcium (2 hours apart) as they compete for absorption
• Vitamin C taken with iron significantly enhances non-heme absorption

4. Magnesium

Magnesium is involved in over 300 enzymatic reactions and is one of the most commonly depleted minerals during caloric restriction. It is not routinely checked in standard labs, which means deficiency frequently goes undetected. Symptoms of low magnesium include muscle cramps (particularly at night), fatigue, insomnia, anxiety, and irregular heartbeat.

• Supplement: 200–400 mg magnesium glycinate daily — this chelated form is the best tolerated and least likely to cause loose stools
• Magnesium oxide is poorly absorbed and not recommended for deficiency correction
• Take in the evening — magnesium has a mild relaxation effect that may improve sleep
• Check serum magnesium at baseline; note that serum levels do not reflect total body stores accurately

5. Calcium

Reduced intake of dairy products as appetite decreases is the primary driver of calcium insufficiency on GLP-1 therapy. Adequate calcium is essential for bone health, and this matters particularly during rapid weight loss — a state that is independently associated with bone density loss. Combined with potential vitamin D insufficiency, calcium-related bone risk is real over years of therapy.

• Target total intake (diet + supplement): 1,000–1,200 mg daily
• Calcium citrate is better absorbed than calcium carbonate, especially when stomach acid is reduced
• Do not take calcium and iron supplements at the same time — they compete for absorption
• Split calcium into two doses of 500–600 mg for better absorption rather than one large dose

6. Zinc

Zinc is essential for immune function, wound healing, and taste perception. Interestingly, the altered taste and smell that some patients experience on GLP-1 medications may partly relate to zinc status, since zinc is required for taste receptor function. Reduced intake of zinc-rich foods (red meat, shellfish, legumes) during appetite suppression can create a functional deficit.

• Recommended daily intake: 8 mg (women) to 11 mg (men); supplement at these levels if dietary intake is low
• Zinc picolinate or zinc glycinate are better-absorbed forms
• Avoid taking zinc with calcium supplements as they can compete for absorption
• High-dose zinc (>40 mg/day) can deplete copper — do not over-supplement

7. Thiamine (Vitamin B1)

Thiamine deficiency is rare but potentially serious on GLP-1 therapy, particularly in patients who experience persistent nausea and vomiting. Thiamine stores last only 18–30 days, making it vulnerable to rapid depletion with prolonged reduced intake. Wernicke encephalopathy — a neurological emergency caused by severe thiamine deficiency — has been reported in the context of persistent GLP-1-induced vomiting. Thiamine is included in most standard multivitamins.

Additional Supplements That May Add Value

Beyond the core deficiency-prevention nutrients, several supplements have evidence-based rationale for GLP-1 users specifically:

• Protein powder — If you are consistently falling short of the 100g/day protein target (common with reduced appetite), a high-quality whey or pea protein supplement provides a low-volume, high-density protein source without requiring a large meal.
• Collagen peptides — Growing evidence supports collagen for skin elasticity and joint health. This is particularly relevant during rapid weight loss, when skin changes are common. Look for 10–15g of hydrolyzed collagen peptides daily.
• Omega-3 fish oil — Anti-inflammatory, cardiovascular, and triglyceride-lowering benefits are well-established. 1–3g EPA+DHA daily is a reasonable target. Particularly relevant for patients with existing dyslipidemia or metabolic syndrome.
• Probiotics — GLP-1 medications alter gut motility and the gut microbiome. Some patients report relief from constipation and GI discomfort with multi-strain probiotics. Evidence is still emerging but the risk-benefit profile is favorable.
• Psyllium husk (fiber supplement) — Constipation is one of the most common complaints on GLP-1 therapy. Daily psyllium husk (5–10g with plenty of water) improves stool consistency and reduces straining, and has additional benefits for cholesterol and blood sugar management.

Lab Monitoring Schedule

Because no official GLP-1 nutritional monitoring guidelines exist, the following schedule is based on obesity medicine and endocrinology expert recommendations:

1. Baseline (before or at start of therapy): Complete blood count (CBC), comprehensive metabolic panel, serum B12, 25-OH vitamin D, ferritin, zinc, magnesium, lipid panel, HbA1c
2. 3 months: Follow up on any baseline abnormalities; assess GI symptoms and dietary intake
3. 6 months: Repeat B12, vitamin D, ferritin, CBC; adjust supplementation based on results
4. 12 months and annually thereafter: Full nutritional panel including the above; consider bone density (DEXA) if on long-term therapy with significant weight loss
5. At any time: Recheck relevant markers if new symptoms appear (fatigue, tingling, hair loss, muscle weakness)

The Multivitamin Question

A daily multivitamin is a reasonable baseline for GLP-1 users, but it is not sufficient on its own. Most multivitamins contain low doses of key nutrients and often use poorly absorbed forms (e.g., cyanocobalamin instead of methylcobalamin, calcium carbonate, magnesium oxide). Think of a multivitamin as a safety net, not a comprehensive solution. Targeted supplementation based on your specific labs is always superior to a one-size-fits-all approach.

Key Takeaways

• More than 22% of GLP-1 users develop nutritional deficiencies within 12 months — proactive monitoring is essential.
• Priority nutrients to monitor and supplement: B12, vitamin D, iron, magnesium, calcium, zinc, and thiamine.
• Sublingual or methylcobalamin B12 is preferred over standard oral forms for GLP-1 users due to reduced gastric acid.
• Magnesium glycinate and calcium citrate are the best-absorbed forms when gastric acid is reduced.
• Schedule lab work at baseline, 6 months, and annually — do not wait for symptoms to appear.
• Discuss all supplementation with your prescribing provider, especially if you take other medications.

Sources

• Drucker DJ (2018). Mechanisms of Action and Therapeutic Application of GLP-1. Cell Metabolism.
• Wilding et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM.